Bespak maintains improved performance:
This article was originally published in Clinica
Executive Summary
Strong demand for its asthma inhaler valves drove first-half sales and profit increases at Bespak, the UK-based drug delivery device manufacturer. Sales rose by 10.4% to £39.4 million ($67 million) in the six months to November 1st, 1996. Pre-tax profit for the half year was 42.9% ahead of year-earlier figures, at £5 million. Bespak, which returned to profitability in fiscal 1996, is forecasting continued progress through the second half-year. The company expects further growth in UK sales of drug delivery devices, and anticipates improved profitability for its US operations.